Cancer as an endocrine problem

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 22, Issue 4, 2008, Pages 539-550

  Holly, Jeff M P ^a   Perks, Claire M ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

context; metabolism; nutrition; prevention

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; BETA CAROTENE; BOMBESIN; BRCA1 PROTEIN; BRCA2 PROTEIN; GHRELIN; GONADORELIN; GROWTH HORMONE RELEASING FACTOR; LEPTIN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B; PROTEIN P53; RETINOL; SEX HORMONE; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOSTATIN; TRICARBOXYLIC ACID;

AUTOPSY; BREAST CANCER; CALORIC RESTRICTION; CANCER SCREENING; CARCINOGENESIS; CELL METABOLISM; CITRIC ACID CYCLE; CLINICAL TRIAL; COLORECTAL CANCER; DIET SUPPLEMENTATION; DIGITAL RECTAL EXAMINATION; DISEASE ASSOCIATION; DRUG MEGADOSE; ENDOCRINOLOGY; ENERGY BALANCE; ENVIRONMENTAL EXPOSURE; FEEDING BEHAVIOR; GENE MUTATION; HEREDITY; HIGH FIBER DIET; HORMONAL REGULATION; HUMAN; LOW FAT DIET; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; METABOLIC SYNDROME X; METABOLISM; MORBIDITY; NUTRITION; NUTRITIONAL STATUS; OBESITY; POPULATION MIGRATION; PROPHYLAXIS; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION;

FEMALE; HUMANS; MALE; NEOPLASMS; NEUROSECRETORY SYSTEMS; SIGNAL TRANSDUCTION;

EID: 54349123605     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2008.07.007     Document Type: Review

References (62)

1. Thompson P.A. Counterpoint: genetic risk feedback for common disease time to test the waters. Cancer Epidemiology, Biomarkers & Prevention 16 9 (2007) 1727-1729
2. Doll R., and Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. Journal of the National Cancer Institute 66 6 (1981) 1191-1308
3. Doll R. Epidemiological evidence of the effects of behaviour and the environment on the risk of human cancer. Recent Results in Cancer Research 154 (1998) 3-21
4. Peto J. Cancer epidemiology in the last century and the next decade. Nature 411 6835 (2001) 390-395
5. Tominaga S., and Kuroishi T. An ecological study on diet/nutrition and cancer in Japan. International Journal of Cancer Suppl 10 (1997) 2-6
6. Michels K.B., and Willett W.C. Breast cancer-early life matters. The New England Journal of Medicine 351 16 (2004) 1679-1681
7. Lichtenstein P., Holm N.V., Verkasalo P.K., et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. The New England Journal of Medicine 343 2 (2000) 78-85
8. King M.C., Marks J.H., and Mandell J.B. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302 5645 (2003) 643-646
9. Tryggvadottir L., Sigvaldason H., Olafsdottir G.H., et al. Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000. Journal of the National Cancer Institute 98 2 (2006) 116-122
10. Nkondjock A., Robidoux A., Paredes Y., et al. Diet, lifestyle and BRCA-related breast cancer risk among French-Canadians. Breast Cancer Research and Treatment 98 3 (2006) 285-294
11. Vineis P. Cancer as an evolutionary process at the cell level: an epidemiological perspective. Carcinogenesis 24 1 (2003) 1-6
12. Green D.R., and Evan G.I. A matter of life and death. Cancer Cell 1 1 (2002) 19-30
13. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 1 (2000) 57-70
14. Jonason A.S., Kunala S., Price G.J., et al. Frequent clones of p53-mutated keratinocytes in normal human skin. Proceedings of the National Academy of Sciences of the United States of America 93 24 (1996) 14025-14029
15. Halpern M.T., Gillespie B.W., and Warner K.E. Patterns of absolute risk of lung cancer mortality in former smokers. Journal of the National Cancer Institute 85 6 (1993) 457-464
16. Renehan A.G., Bhaskar P., Painter J.E., et al. The prevalence and characteristics of colorectal neoplasia in acromegaly. The Journal of Clinical Endocrinology and Metabolism 85 9 (2000) 3417-3424
17. Delongchamps N.B., Singh A., and Haas G.P. The role of prevalence in the diagnosis of prostate cancer. Cancer Control 13 3 (2006) 158-168
18. Sakr W.A., Grignon D.J., Crissman J.D., et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo (Athens, Greece) 8 3 (1994) 439-443
19. Sheldon C.A., Williams R.D., and Fraley E.E. Incidental carcinoma of the prostate: a review of the literature and critical reappraisal of classification. The Journal of Urology 124 5 (1980) 626-631
20. Yatani R., Shiraishi T., Nakakuki K., et al. Trends in frequency of latent prostate carcinoma in Japan from 1965-1979 to 1982-1986. Journal of the National Cancer Institute 80 9 (1988) 683-687
21. Yatani R., Chigusa I., Akazaki K., et al. Geographic pathology of latent prostatic carcinoma. International Journal of Cancer 29 6 (1982) 611-616
22. Watanabe M., Nakayama T., Shiraishi T., et al. Comparative studies of prostate cancer in Japan versus the United States. A review. Urologic Oncology 5 6 (2000) 274-283
23. Shiraishi T., Watanabe M., Matsuura H., et al. The frequency of latent prostatic carcinoma in young males: the Japanese experience. In Vivo (Athens, Greece) 8 3 (1994) 445-447
24. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. The New England Journal of Medicine 350 22 (2004) 2239-2246
25. Gosselaar C., Roobol M.J., and Schroder F.H. Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant?. BJU International 95 2 (2005) 231-237
26. Carroll K.K. Experimental evidence of dietary factors and hormone-dependent cancers. Cancer Research 35 11 Pt. 2 (1975) 3374-3383
27. Ganmaa D., Li X.M., Wang J., et al. Incidence and mortality of testicular and prostatic cancers in relation to world dietary practices. International Journal of Cancer 98 2 (2002) 262-267
28. Michels K.B., Mohllajee A.P., Roset-Bahmanyar E., et al. Diet and breast cancer: a review of the prospective observational studies. Cancer 109 12 Suppl (2007) 2712-2749
29. Alberts D.S., Martínez M.E., Roe D.J., et al. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. The New England Journal of Medicine 342 16 (2000) 1156-1162
30. Lanza E., Yu B., Murphy G., et al. The polyp prevention trial continued follow-up study: no effect of a low-fat, high-fiber, high-fruit, and -vegetable diet on adenoma recurrence eight years after randomization. Cancer Epidemiology, Biomarkers & Prevention 16 9 (2007) 1745-1752
31. Cole B.F., Baron J.A., Sandler R.S., et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. The Journal of the American Medical Association 297 21 (2007) 2351-2359
32. Albanes D., Heinonen O.P., Taylor P.R., et al. Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. Journal of the National Cancer Institute 88 21 (1996) 1560-1570
33. Hord N.G., and Fenton J.I. Context is everything: Mining the normal and preneoplastic microenvironment for insights into the diet and cancer risk conundrum. Molecular Nutrition & Food Research 51 1 (2007) 100-106
34. Calle E.E., Rodriguez C., Walker-Thurmond K., et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. The New England Journal of Medicine 348 17 (2003) 1625-1638
35. Calle E.E., and Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nature Reviews. Cancer 4 8 (2004) 579-591
36. Hsu I.R., Kim S.P., Kabir M., et al. Metabolic syndrome, hyperinsulinemia, and cancer. The American Journal of Clinical Nutrition 86 3 (2007) s867-s871
37. Pollak M. Insulin, insulin-like growth factors, insulin resistance, and neoplasia. The American Journal of Clinical Nutrition 86 suppl (2007) 820s-822s
38. Warburg O. On the origin of cancer cells. Science 123 3191 (1956) 309-314
39. Bensaad K., Tsuruta A., Selak M.A., et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126 1 (2006) 107-120
40. Kawauchi K., Araki K., Tobiume K., et al. p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nature Cell Biology 10 5 (2008) 611-618
41. Magnard C., Bachelier R., Vincent A., et al. BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT domains. Oncogene 21 44 (2002) 6729-6739
42. Brunet J., Vazquez-Martin A., Colomer R., et al. BRCA1 and acetyl-CoA carboxylase: The metabolic syndrome of breast cancer. Molecular Carcinogenesis (2007)
43. Holly J.M., Smith C.P., Dunger D.B., et al. Relationship between the pubertal fall in sex hormone binding globulin and insulin-like growth factor binding protein-I. A synchronized approach to pubertal development?. Clinical Endocrinology 31 3 (1989) 277-284
44. Roddam A.W., Allen N.E., Appleby P., et al. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. Journal of the National Cancer Institute 100 3 (2008) 170-183
45. Stoler D.L., Chen N., Basik M., et al. The onset and extent of genomic instability in sporadic colorectal tumor progression. Proceedings of the National Academy of Sciences of the United States of America 96 26 (1999) 15121-15126
46. Tomlinson I., Sasieni P., and Bodmer W. How many mutations in a cancer?. The American Journal of Pathology 160 3 (2002) 755-758
47. Wood L.D., Parsons D.W., Jones S., et al. The genomic landscapes of human breast and colorectal cancers. Science 318 5853 (2007) 1108-1113
48. Sjoblom T. Systematic analyses of the cancer genome: lessons learned from sequencing most of the annotated human protein-coding genes. Current Opinion in Oncology 20 1 (2008) 66-71
49. Vogelstein B., and Kinzler K.W. Cancer genes and the pathways they control. Nature Medicine 10 8 (2004) 789-799
50. Bardelli A., and Velculescu V.E. Mutational analysis of gene families in human cancer. Current Opinion in Genetics & Development 15 1 (2005) 5-12
51. Vona-Davis L., and Rose D.P. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocrine-Related Cancer 14 2 (2007) 189-206
52. Garofalo C., and Surmacz E. Leptin and cancer. Journal of Cellular Physiology 207 1 (2006) 12-22
53. Cascio S., Bartella V., Auriemma A., et al. Mechanism of leptin expression in breast cancer cells: role of hypoxia-inducible factor-1alpha. Oncogene 27 4 (2008) 540-547
54. Arditi J.D., Venihaki M., Karalis K.P., et al. Antiproliferative effect of adiponectin on MCF7 breast cancer cells: a potential hormonal link between obesity and cancer. Hormone and Metabolic Research 39 1 (2007) 9-13
55. Barb D., Neuwirth A., Mantzoros C.S., et al. Adiponectin signals in prostate cancer cells through Akt to activate the mammalian target of rapamycin pathway. Endocrine-Related Cancer 14 4 (2007) 995-1005
56. Goffin V., Touraine P., Culler M.D., et al. Drug insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia?. Nature Clinical Practice. Endocrinology & Metabolism 2 10 (2006) 571-581
57. Mukhina S., Mertani H.C., Guo K., et al. Phenotypic conversion of human mammary carcinoma cells by autocrine human growth hormone. Proceedings of the National Academy of Sciences of the United States of America 101 42 (2004) 15166-15171
58. Pandey V., Perry J.K., Mohankumar K.M., et al. Autocrine human growth hormone stimulates oncogenicity of endometrial carcinoma cells. Endocrinology (2008)
59. Schally A.V., Varga J.L., and Engel J.B. Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. Nature Clinical Practice. Endocrinology & Metabolism 4 1 (2008) 33-43
60. Schally A.V. New approaches to the therapy of various tumors based on peptide analogues. Hormone and Metabolic Research 40 5 (2008) 315-322
61. Yeh A.H., Jeffery P.L., Duncan R.P., et al. Ghrelin and a novel preproghrelin isoform are highly expressed in prostate cancer and ghrelin activates mitogen-activated protein kinase in prostate cancer. Clinical Cancer Research 11 23 (2005) 8295-8303
62. Lanfranco F., Baldi M., Cassoni P., et al. Ghrelin and prostate cancer. Vitamins and Hormones 77 (2008) 301-324